is associated with significant, albeit modest, increases in levels Increase in plasma esterified F 2 -isoprostanes following intraof F 2 -isoprostanes esterified in plasma lipoproteins that tended venous iron infusion in patients on hemodialysis.
Iron infused intravenously in large doses may exceed most specific measures of lipid peroxidation available, namely the binding capacity of transferrin and lead to the availgas chromatography/mass spectometry (GC/MS) analysis of F 2 -ability of unbound iron in the blood [1, 2] . Unbound iron isoprostanes. Using a prospective design, blood samples were can catalyze by the Haber-Weiss reaction, thus generating collected 15 minutes before (pre) and 30 minutes after (post) highly reactive hydroxyl radicals that promote lipid pera one-hour infusion of 700 mg bolus of intravenous iron in 22 adult home-hemodialysis patients on a non-hemodialysis day.
oxidation. A prevailing and experimentally supported
Results. With iron-dextran infusion, serum iron markedly mechanism for atherogenesis is based on free radical- lates adhesion molecules [3, 4] . The leading cause of levels of serum iron correlated directly with pre-infusion levels mortality in the dialysis population is cardiovascular disof esterified F 2 -isoprostanes (r ϭ 0.56, P ϭ 0.008), which persisted in the postinfusion period (r ϭ 0.43, P ϭ 0.04). However, ease related to coronary atherosclerosis [5] . In theory, there was no correlation between esterified F 2 -isoprostanes and repeated intravenous iron infusion can promote LDL perserum ferritin levels. In the last four patients in whom blood oxidation and, through the aforementioned mechanism, samples were collected five hours after the intravenous iron may accelerate atherosclerosis in dialysis population. Poinfusion, there were further increases in esterified F 2 -isoprostentially this may worsen the already elevated mortality tanes that very closely correlated with postinfusion serum iron levels (r ϭ 0.99, P ϭ 0.013). In a control study, the in vitro rate in the dialysis population and undermine the beneaddition of iron dextran to blood samples did not increase free fits of improved anemia correction from repeated intraor esterified F 2 -isoprostanes, suggesting that the increase in estervenous iron infusion. The suggestive evidence that inified F 2 -isoprostanes seen in vivo after iron infusion in patients creased intravenous iron administration may increase is not due to a procedural artifact.
the risk for cardiac events comes from Besarab et al's
Conclusion. Collectively our data suggest that high levels of serum iron appearing soon after a large bolus of iron infusion study in which higher cardiac events and mortality were observed in the normal hematocrit (Hct) group who, among other things, also received more intravenous iron Recent studies using plasma malondialdehyde (MDA) measured by the thiobarbituric acid-reacting substances  2001 by the International Society of Nephrology (TBA) test and plasma peroxides suggested that intrahad to be clinically stable, established on home hemodialysis for at least six months, and scheduled for intravenous iron infusion is associated with marked lipid peroxidation [2] . However, these methods are nonspecific venous iron administration based on clinical indication. No change was made in the routine intravenous ironand are subject to false positive results. Measurements of peroxides can be used in studies on purified lipids, but infusion protocol for the study except that blood samples were collected before and after iron infusion. Prior to its use in the biological system is questionable due to interference from many other oxidized species present the study, the patients' demographics, medication and dialysis details, and clinical conditions were assessed. in plasma [7] . Similarly, lipid peroxidation determination based on the TBA test, which involves heating the testing Also obtained was the dose of total iron infused in each of the study subjects during the preceding 12 months. material with thiobarbituric acid and measuring the pink color formed in the process at 532 nm, can provide spuri-
The dose of iron dextran administered to our patients on home-hemodialysis was 700 mg and was ordered by ous positive results [7] . The lack of specificity of the TBA assay when applied to human plasma is amply demonthe patient's nephrologist based on a "need-based" indication for iron repletion. The iron-infusion studies in all strated by the work of Warso and Lands and is discussed in detail by Halliwell and Gutteridge [8, 9] . Use of iron 22 patients were carried out by the same research nurse (BO), and the iron dextran preparation used in this study by an intravenous route has turned out to be a boon for the management of anemia in dialysis patients as it is was from Schein Pharmaceutical Inc. (Florham Park, NJ, USA). Iron infusion was carried out on a non-dialysis simple, efficacious, and generally safe. Thus, it is critical to verify whether there is a true occurrence of lipid perday to avoid any confounding effect of hemodialysis on the study. Pre-iron-infusion samples were collected 15 minoxidation with iron infusion and, if so, whether there is peroxidation of lipoproteins, an event considered critical utes prior to administration of iron including the test dose. A 21-gauge plastic catheter was inserted in the patient's in atherogenesis. We addressed this issue using one of the most specific measures of lipid peroxidation currently hemodialysis vascular access to draw blood samples. A needleless system with a Leur-lock adapter was attached available, namely gas chromatography/mass spectometry to the catheter and flushed with 2 mL 0.9% saline. A (GC/MS) measurement of F 2 -isoprostanes [10] . These 1 mL waste was drawn prior to all collections to eliminate are formed in vivo by the free radical-induced peroxidathe possibility of diluting the samples by the saline. All tion of arachidonic acid, independent of the cyclooxygeniron dextran, including the test dose, was administered ase enzyme [11] . Unlike the cyclooxygenase-catalyzed via a peripheral infusion site in the extremity opposite prostaglandin production, F 2 -isoprostanes are initially the blood-sampling site. All samples were drawn into a formed in situ esterified to tissue lipids and circulating prechilled syringe and transferred to a prechilled transfer lipoproteins, and subsequently are released in free form tube. A 5 mL tube with potassium ethylenediaminetetra- [12, 13] . A large body of evidence in experimental aniacetic acid (EDTA) was used for the F 2 -isoprostanes mals and humans indicates that measurement of F 2 -isosamples, and a 10 mL SST Gel and clot activator tube prostanes represent one of the most reliable approaches was used to collect the other iron-related measurements. to assess lipid peroxidation including LDL peroxidation Samples for F 2 -isoprostanes were immediately centriand oxidant stress in vivo [10, 14, 15] . fuged, and plasma was transferred to a prechilled transfer To test whether intravenous iron infusion is associated tube and submerged in dry ice until transport to the with an increase in free and esterified plasma F 2 -isopros-Ϫ84ЊC freezer for storage. All infusions were timed to tanes, plasma samples were prospectively collected just run for one hour. The postinfusion samples were drawn before and one half hour after the one-hour infusion 30 minutes after the completion of iron infusion. In last (700 mg) of iron dextran in home hemodialysis patients four patients, an additional sample was drawn at five on a non-hemodialysis day. The results demonstrate that hours postinfusion (late post) to determine whether there there was a modest increase in F 2 -isoprostanes esterified was a time-related increase in plasma F 2 -isoprostanes after on plasma lipoproteins that correlated with serum iron iron infusion. A control study was also undertaken to concentration, suggestive of the occurrence of iron-induced determine whether processing of the sample for F 2 -isolipid peroxidation.
prostanes could lead to ex vivo F 2 -isoprostane formation. For this study, iron dextran was added to blood samples METHODS from healthy volunteers to obtain similar iron levels as The study protocol, which was approved by the Instituin patients after iron infusion. Samples were then protional Review Board of University of Mississippi Medical cessed in the same fashion as the patients' samples and Center, was carried out prospectively in 22 patients on were subjected to F 2 -isoprostane measurements. home hemodialysis who were managed by the Renal Care Samples were packed in dry ice during shipment to Group Inc. of Jackson (MS, USA). The selection criteria Vanderbilt University for the F 2 -isoprostane measurement, and all samples were verified to have arrived in a were that patients should be between 20 to 75 years old, scribed [17] . The assay has a precision of Ϯ6% and an accuracy of 96%.
Statistical analysis (42 Ϯ 4 vs. 311 Ϯ 92 g/dL, P Ͻ 0.0001). Serum transferrin The StatView computer software program from Abaand ferritin concentrations did not change. cus Concepts, Inc. (Berkley, CA, USA) was used for data analysis. The results are reported as mean Ϯ SEM.
Effect of intravenous iron administration on free and The comparison between pre-iron and post-iron infusion esterified F 2 -isoprostanes groups were carried out by a two-tailed Student t test, Plasma concentrations of free isoprostanes did not and the correlation was assessed by simple linear regreschange significantly following infusion of iron (pre 40 Ϯ sion. P Ͻ 0.05 was considered statistically significant. 5 vs. post 39 Ϯ 6 pg/mL). However, levels of isoprostanes esterified in plasma lipoproteins increased significantly in the postinfusion samples (pre 199 Ϯ 19 vs. post 233 Ϯ RESULTS 25 pg/mL, P Ͻ 0.004; Fig. 1A ). The levels rose in 16 out Patient characteristics of 22 patients, fell in four, and were unchanged in two Twenty-two patients on home hemodialysis were stud- (Fig. 1B) . ied. These patients were dialyzed three times weekly for
In the last four patients in whom a five-hour post four hours each session. The mean age was 48 Ϯ 3 years.
infusion sample was collected (late post), the free isoThe mean duration on dialysis was 114 Ϯ 21 months.
prostanes did not increase. The pre-, post-, and late-post Twelve patients were male. Twelve were African Amerivalues were 33 Ϯ 6, 29 Ϯ 4, and 28 Ϯ 2 pg/mL, respeccans, and 10 were Caucasians. Diabetes mellitus was retively. However, the mean esterified isoprostanes did corded as the cause for end-stage renal disease (ESRD) increase with time insignificantly (N ϭ 4) , and the respecin 4, hypertension in 11, and glomerulonephritis in 7, tive levels were 332 Ϯ 39, 379 Ϯ 60, and 398 Ϯ 46 pg/mL. and 2 patients were cigarette smokers. The mean body mass index (BMI) was 27.3 Ϯ 1.6. Serum albumin was Relationship between esterified isoprostanes and 4.30 Ϯ 0.07 g/dL. Kt/V was 1.25 Ϯ 0.09, and predialysis serum iron and iron-related parameters serum creatinine was 12 Ϯ 0.8 mg/dL. All patients used
There was a significantly positive correlation between modified cellulose acetate dialysis membranes. The mean levels of serum iron and esterified isoprostanes prior to epoetin dose was 4486 Ϯ 826 units, and the Hct was iron infusion (r ϭ 0.56, P ϭ 0.008; Fig. 2A ). Following 34.2 Ϯ 0.8. The mean dose of intravenous iron received iron infusion, serum iron levels rose rapidly and the relaby the patients in the preceding 12 months was 1.83 Ϯ tionship between iron levels and esterified isoprostanes, 0.20 g.
while persistent, became weak soon after iron infusion Effect of intravenous iron administration on serum (r ϭ 0.44, P ϭ 0.042; Fig. 2B ). In four patients in whom iron and iron-related parameters plasma-esterified isoprostanes were measured five hours after the completion of iron infusion, there was a remarkAll the patients received 700 mg of iron dextran as a ably close correlation between the five-hour post infusion one-hour intravenous bolus, and no side effects were levels of iron and esterified isoprostanes (r ϭ 0.99, P ϭ reported. The BP did not change significantly with an 0.013; Fig. 2C ). Transferrin saturation showed a positive intravenous iron infusion. The serum iron and iron-related correlation with the pre-iron infusion levels of esterified parameters taken 15 minutes before and 30 minutes after isoprostanes (r ϭ 0.49, P ϭ 0.022), but this was lost after the one-hour infusion of 700 mg iron dextran are given in iron infusion as transferrin saturation in 22 out of 22 Table 1 . With iron dextran infusion, transferrin saturation exceeded 100% (r ϭ 0.10, P ϭ 0.68). There was no corre-(serum iron/TIBC ϫ 100) exceeded 100% in 22 patients lation between plasma isoprostanes and serum ferritin (pre 23 Ϯ 3 vs. post 165 Ϯ 8%, P Ͻ 0.0001), and this was associated with a significant increase in serum iron levels either before or after iron infusion.
iron dextran infusion that appear to exceed the binding capacity of transferrin were not immediately associated with generalized lipid peroxidation. However, the findings of a modest but significant increase in plasma esterified F 2 -isoprotanes after iron infusion and the presence of a strong correlation between esterified isoprostanes and serum iron concentrations suggest that iron infusion may cause low-grade and ongoing peroxidation of lipids in the plasma, which are contained in lipoproteins. Iron and other redox metal ions are strong catalysts for LDL oxidation and, as alluded to earlier, the latter is widely regarded as a seminal process in the pathogenesis of atherosclerosis [3, [18] [19] [20] . Sullivan hypothesized a link between body iron and atherosclerosis to explain the gender difference in the incidence of heart disease [21], and some, but not all, studies support an association between high levels of iron and the occurrence of heart disease [22-27]. Employing a more specific measurement of body iron stores such as the ratio of serum transferrin receptor to serum ferritin, a recent prospective study showed an association between increased body iron stores and an excess risk for myocardial infarction in the general population [22, 28] . Data in our study demonstrate a strong correlation (r ϭ 0.56) between the concentrations of serum iron and plasma-esterified F 2 -isoprostanes, suggesting that higher plasma iron concentrations lead to enhanced lipoprotein peroxidation. For these measure- Lab, Inc.). Further, samples were carefully collected and processed to minimize any possibility for ex vivo ironinduced lipid peroxidation. Our observation that there Effect of in vitro addition of iron dextran to blood on was strong correlation between plasma iron and F 2 -isoisoprostane levels prostanes in the samples collected prior to iron infusion points away from the possibility of spurious ex vivo ironTo determine whether the increase in esterified isoinduced F 2 -isoprostane formation. Finally, the negative prostanes in patients after intravenous iron infusion results of the control experiment involving the addition could be a procedural artifact, that is, ex vivo autoxidaof iron dextran to plasma prior to storage and analysis tion, iron dextran was added to blood samples from five of isoprostanes also strongly suggest that the increase in healthy volunteers (3 males, age 36 Ϯ 5 years, serum levels of esterified isoprostanes seen in plasma from ironcreatinine 0.9 Ϯ 0.1 mg/dL) such that the serum iron infused patients is not due to procedural artifact. levels rose from 105 Ϯ 11 to 336 Ϯ 35 g/dL, P Ͻ 0.0001.
The time-related slow increase in esterified isoprosNo differences were seen in the levels of F 2 -isoprostanes tanes noted in the last four patients in whom five-hour in plasma to which iron had been added compared to post infusion samples were collected suggests that lipid levels in plasma to which no iron had been added. Free peroxidation following iron infusion is a slow accruing isoprostanes before and after added iron were 71.0 Ϯ process. Our study did not show any significant increase 9.5 and 71.7 Ϯ 9.5 pg/mL, and the respective values for in free F 2 -isoprostanes that often occur with generalized esterified isoprostanes were 287.8 Ϯ 34.5 and 280.6 Ϯ lipid peroxidation, but rather increases were limited to 33.5 pg/mL. F 2 -isoprostanes esterified in lipids in the plasma compartment. The explanation of why the increased lipid peroxi-DISCUSSION dation appears not to be generalized but compartmentalOur study, based on the measurement of free plasma ized to plasma lipids remains to be established, but could be due to the fact that lipids in the plasma are likely F 2 -isoprostane levels, demonstrates that large doses of Fig. 2. (A) Simple regression analysis between serum iron concentration and plasma-esterified isoprostane levels prior to the infusion of iron. There was a significant positive correlation (r ϭ 0.56, P ϭ 0.008) between pre-infusion levels of serum iron and esterified isoprostanes. (B) Simple regression analysis between serum iron concentration and plasma-esterified isoprostane levels after the infusion of iron dextran showing a persistent positive correlation (r ϭ 0.43, P ϭ 0.04). Iron dextran was infused in 22 home-hemodialysis patients at 700 mg over one hour on a non-hemodialysis day, and plasma samples were collected 30 minutes afterwards. (C) Simple regression analysis between esterified F 2 -isoprostanes measured five hours after iron infusion versus serum iron levels 30 minutes after iron infusion. In the last four patients plasma esterified isoprostanes were measured five hours after the completion of iron infusion to determine whether there was a time dependency on ironinduced esterified F 2 -isoprostane formation (Results section). There is a much stronger correlation between the five-hour post infusion of esterified isoprostanes and serum iron (r ϭ 0.99, P ϭ 0.013) in this panel than between 30 minutes of post-infusion esterified F 2 -isoprostanes and serum iron displayed in panel B.
exposed to a higher concentration of iron during intraveIron administration by the intravenous route is the most effective and convenient way to administer iron in nous infusion than lipids in peripheral tissues.
The marked increase in lipid peroxidation noted in dialysis patients receiving erythropoietin. In recent studies that employed iron administration by the intravenous one previous study could be due, at least in part, to the occurrence of spurious lipid peroxidation in vitro [2] .
route, there was a significant reduction in the erythropoietin dose while maintaining target hemoglobin levels While employment of high-pressure liquid chromatography (HPLC) achieves greater specificity in separating [30, 31] . However, this was associated with an iron administration-related steady increase in serum ferritin levels the TBA-MDA adduct from the reaction mixture, it must be noted that exposure of carbohydrates and amino [30, 31] . In our own database comprising the Mississippi cohort of the Renal Care Group, Inc. hemodialysis paacids to hydroxyl radicals yields products that give a genuine TBA-MDA adduct in the TBA assay [9] . Thus, tients, we compared 1450 patients in December of 1996 with 1639 patients in December of 1998 [32] . The use of TBA assay used in the previous study is not specific for lipid peroxidation [2] . An additional issue with TBA iron by an intravenous route increased dramatically, as did the rest of the U.S. dialysis population [33] . With method is that MDA can be formed in vitro during the assay procedure, and its application to human body fluids this, there was a modest improvement in anemia management, but there was also a twofold increase in the number also will measure endoperoxides produced enzymically by the prostaglandin synthesis pathway [9] . Moreover, of patients with serum ferritin over 1000 ng/mL. Currently, a liberal upper limit is set for iron infusion, that platelets are activated and generate thromboxane during sampling of blood, and the thromboxane synthase generis, a TSAT of 50% and a ferritin of 800 ng/mL to facilitate the correction of functional iron deficiency [34] . A large ates one molecule of MDA for each molecule of thromboxane formed [29] . For these considerations, we adportion of the iron infused into patients with functional iron deficiency will not be utilized for red cell formation, dressed this issue using one of the most specific measures of lipid peroxidation available, namely GC/MS analysis but will be sequestrated into storage iron as demonstrated by the increase in ferritin levels in the above-mentioned of F 2 -isoprostanes [10, 14, 15] . studies. Whether an increase in this form of body iron Roob et al reported the occurrence of lipid peroxidation even with 100 mg of iron sucrose infusion [2] . In that may lead to toxicity is unlikely, because the iron in ferristudy, however, iron was infused while the patients were tin is in the storage form and is not readily bioavailable.
undergoing hemodialysis. Hemodialysis might in itself Consistently, ferritin levels did not influence F 2 -isoprosprovoke oxidative stress through a number of mechatane levels in this study. Furthermore, that the high level nisms [37, 38] and, therefore, it is possible that ongoing of ferritin per se may not directly contribute to iron hemodialysis procedure might set the stage for a greater toxicity is supported also by the observation of the lack oxidative stress even at a lower dose of iron infusion. of undue atherosclerosis in patients and models of hemStudies using more specific measures of oxidative stress ochromatosis [26, 35] . Unlike ferritin, our study suggests such as F 2 -isoprostane measurements by mass spectrosthat the high levels of serum iron that often accompany copy are required to verify whether iron infusion at 100 high TSAT might become available for catalyzing lipid mg per dose is devoid of any potential oxidative effect. peroxidation. Thus, the concern ought to be about the A significant increase in esterified F 2 -isoprostanes retoxicity of high peak concentrations of iron in the blood, flects the increase in total plasma lipoprotein oxidation, which occurs during and days immediately following the considered mostly to be of LDL origin, as LDL form intravenous bolus of large quantities of iron [31] . Smaller the bulk and are susceptible to oxidation [39, 40] . There doses of iron administered over the duration of each dialwere only four patients with diabetes mellitus in this ysis can avoid the high peak and trough levels of iron. This study, and their pre-iron or post-iron infusion of esterified will avoid potentially overloading the binding capacity of isoprostanes was not different from the rest of the study transferrin. If iron was administered at a lower dose (that subjects. Our patients were routinely prescribed nonis, 12.5 to 25 mg) and more frequently (that is, each vitamin E-containing multivitamins, but none was on dialysis over 4 hours), the bioavailable iron could be vitamin E. One patient took over-the-counter multivitaexpected to be present persistently without the risk for mins. Thus, the reason for the modest increase noted in high serum iron levels and transferrin supersaturation.
esterified isoprostanes in this study or lack of increase in Thus, administering lower doses of iron more frequently, esterified isoprostanes in four patients with iron infusion at least in theory, is unlikely to lead to plasma lipoprotein cannot readily be ascribed to variability due the effect peroxidation and tissue iron deposition.
of any significant antioxidant intake. However, studies Although our patients were on home hemodialysis, are required to test whether antioxidants can attenuate to receive the intravenous iron dextran infusion under iron-induced increase in plasma F 2 -isoprostanes. medical supervision, they attended a dialysis center. These When this study was designed, we predicted that if there patients were not on dialysis on the day of infusion. The were to be lipid peroxidation after intravenous blousing clinical routine was that a "total dose" of 700 mg iron of iron, it would likely be present within an hour or two dextran was to be infused once a month until iron stores of infusion. The finding that isoprostane levels increases were replete. Our finding that iron dextran infusion in at five hours after infusion suggested that lipid peroxidalarge doses can exceed the transferring binding and lead tion after iron infusion is a slow and accruing phenometo modest lipid peroxidation suggests that unbound iron non that might take several hours or possibly days to as theorized could be a catalyst for lipid peroxidation.
peak after iron infusion. Consistent with this notion, the In childhood iron poisoning, serum iron concentrations strongest correlation between levels of serum iron and over 250 g/dL can be high enough to exceed the total esterified isoprostanes was seen in the pre-infusion levels. number of transferrin binding sites in serum [36] . HowIn summary, these data indicate that infusion of high ever, it should be noted that certain types of serum assays doses of iron is associated with very high levels of serum for iron measure the iron present in iron complexes spuiron, saturation of transferrin, and significant, albeit modriously. This is particularly true for ferric gluconate rather est, increase in F 2 -isoprostanes esterified in plasma lipothan the iron dextran used in our study, and can lead to proteins. Although it is uncertain whether this degree of erroneously high results for the oversaturation of translipoprotein oxidation may have deleterious effects, it may ferrin [16] . The iron assay based on the Ferrozine method be prudent to explore whether this can be prevented by employed in our study also is reported to be more specific modification of the protocol using slow infusion of smaller in that in an in vitro study, the Ferrozine method meaand more frequent doses of iron and, if necessary, that sured only 2.2% (Ϯ1.2%) of the iron present in iron the infusion be along with antioxidant administration. dextran when iron dextran was added to serum [16] .
It is possible that at a lower dose of 100 mg of iron ACKNOWLEDGMENTS dextran typically administered in patients attending limThis study is made possible in part by a grant from the Kidney Care ited-care dialysis facilities, the TSAT may not exceed lipid peroxidation may not occur. On the other hand,
